机构:[1]School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, Guangdong, P. R. China.[2]Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.中山大学肿瘤防治中心[3]Medical School of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.[4]Houston Methodist Hospital, Cancer Center and Research Institute, Houston, Texas, USA.[5]MD Anderson Cancer Center, Houston, Texas, USA. zhiminlu@mdanderson.org[6]Department of Pathology, Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, P. R. China.[7]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.临床科室内科中山大学肿瘤防治中心[8]The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.中山大学附属第一医院[9]Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.临床科室妇科中山大学肿瘤防治中心[10]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China.
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 10 more questions are presented as followed. Question 40. Why do mice being used as tumorigenesis models raised in different places or different conditions possess different tumor formation rate? Question 41. How could we generate more effective anti-metastasis drugs? Question 42. What is the molecular mechanism underlying heterogeneity of cancer cachexia in patients with the same pathologic type? Question 43. Will patients with oligo-metastatic disease be curable by immunotherapy plus stereotactic body radiotherapy? Question 44. Can the Warburg effect regulation be targeted for cancer treatment? Question 45. Why do adenocarcinomas seldom occur in the small intestine? Question 46. Is Epstein-Barr virus infection a causal factor for nasal natural killer/T cell lymphoma formation? Question 47. Why will not all but very few human papillomavirus-infected patients eventually develop cervical cancer? Question 48. Why do cervical carcinomas induced by human papilloma virus have a low mutation rate in tumor suppressor genes? Question 49. Can viral infection trigger lung cancer relapse?
语种:
外文
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版:
无
第一作者:
第一作者机构:[1]School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, Guangdong, P. R. China.
推荐引用方式(GB/T 7714):
Jiangchao Li,Dong-Fang Meng,Zixun Zeng,et al.The 150 most important questions in cancer research and clinical oncology series: questions 40-49[J].CHINESE JOURNAL OF CANCER.2017,36:-.doi:10.1186/s40880-017-0222-7.
APA:
Jiangchao Li,Dong-Fang Meng,Zixun Zeng,Bin S. Teh,Zhimin Lu...&Lan Huang.(2017).The 150 most important questions in cancer research and clinical oncology series: questions 40-49.CHINESE JOURNAL OF CANCER,36,
MLA:
Jiangchao Li,et al."The 150 most important questions in cancer research and clinical oncology series: questions 40-49".CHINESE JOURNAL OF CANCER 36.(2017):-